When: Confirmed base above $1,200 post-earnings with 10 EMA reclaim on volume

Then: Deploy third reserved tranche

Modify trader's plan: defer first tranche to either confirmed retest from above with RSI above 50, or deeper flush to 1,090-1,130 with capitulation volume and RSI below 35; tighten initial position to one-quarter; use 1,050 stop; do not initiate new positions within three trading days of Q2 earnings

• MACD has crossed bearish with histogram at negative 5.81 and expanding; RSI at 45.78 and falling; price below 10 EMA for two consecutive sessions — current 50 SMA test lacks prior bullish conditions
• Trailing PE of 40.8 versus forward PE of 25.5 only works if forward earnings deliver; any incremental hawkish surprise pushes yields higher and compresses multiple further
• Q1 2026 FCF was $2.8 billion versus $6 billion in Q3 2025 — a 54 percent decline in two quarters
• Inventory up 56 percent year-over-year; receivables up 51 percent year-over-year; working capital absorbed $1.7 billion in Q1 alone
• Earnings binary is speculation with directional bias, not true asymmetry — stocks at broken technicals heading into print deliver volatile reactions regardless of headline beat
• Low retail engagement at 1,148 after run from 876 to 1,238 consistent with both early-stage accumulation AND late-stage distribution; aggressive analyst chose confirmation-bias interpretation
• Proposed modification: defer first tranche until successful retest of 50 SMA from above with RSI turning back above 50, OR flush to 1,090-1,130 zone with capitulation volume and RSI below 35
• Tighten initial position to one-quarter of planned overweight rather than one-third
• Do not initiate any new position within three trading days of Q2 earnings print — ATR of $36 makes binary too wide without edge

→ vs aggressive: 50 SMA 'launchpad' narrative pattern-matches the level without differentiating regime — prior tests occurred with MACD positive and expanding, RSI pushing 70 during breakout; current test has MACD bearish with histogram at negative 5.81, RSI at 45.78 and falling

→ vs aggressive: Macro ceiling argument has limited room for relief and meaningful room for incremental pressure — trailing PE of 40.8 only works if forward earnings deliver; symmetry the aggressive analyst claims is actually tilted the other way when accounting for duration risk on hyper-growth name

→ vs aggressive: FCF bullish narrative uses long-run capacity build to justify ignoring near-term cash conversion risk — 54 percent FCF decline in two quarters with inventory up 56 percent YoY and receivables up 51 percent YoY creates real write-down and margin compression risk heading into Q2 earnings

→ vs aggressive: Earnings binary framing constructs 'asymmetric bet' using forward-looking confidence about unoccurred event — that is speculation with directional bias, not asymmetry; historical beat rate for pharma earnings when stock is up 50 percent off lows testing 50 SMA heading into print is not a high probability setup

→ vs aggressive: Retail silence equals bullish argument proves too much — low retail engagement at 1,148 after run from 876 to 1,238 is equally consistent with late-stage distribution where institutions who bought at 876 have distributed into the rally and are waiting for retail exit liquidity

BUY

• First tranche: Deploy one-quarter of planned overweight at 1,148 (reduced from one-third); skin in the game if 50 SMA holds but does not overcommit before confirmation
• Second tranche: Buy in 1,090 to 1,120 zone (upper bound tightened from 1,130); targets the mid-June consolidation base with ~5% additional downside from current levels
• Third tranche: Reserve for confirmed base above 1,200 post-earnings; adds only if beat-and-raise materializes and price reclaims 10 EMA and prior resistance
• Stop level: 1,050 is appropriate at 2.7 ATRs (ATR of 36); absorbs normal volatility without getting shaken out
• Trim discipline: Take 35-40% off above 1,400 (more aggressive than the 25-30% suggested by aggressive analyst); locks in the 22% rally from current levels
• Earnings timing: Allow first one-quarter tranche pre-earnings; hold second and third tranches until post-earnings price action confirms
• 50 SMA test context: Close at 1,148.84 vs SMA at 1,147.32; level has been defended multiple times since June but conditions are weaker, warranting smaller initial size
• Concentration risk: LLY is a binary bet in any portfolio; netting against other healthcare exposure and considering correlation with macro environment is critical

→ vs aggressive: Entry timing matters separately from asset quality; buying before a binary earnings event at a bearish MACD crossover is not smart capital use even on a generational franchise

→ vs aggressive: Low retail engagement is a weak bullish signal; it can mean early accumulation, late distribution, or retail has moved on; no evidence to assign probabilities

→ vs aggressive: Cannot simultaneously claim macro is a floor (supporting current multiple) and the Fed will pivot dovishly as an upside catalyst; these positions are inconsistent

→ vs conservative: Three-day hard blackout before earnings is too rigid; the probability of a clean beat-and-raise is meaningfully higher than 50/50 given LLY's consistent hits and asymmetric demand backdrop

→ vs conservative: 50 SMA at 1,147.32 has been defended multiple times; weaker conditions warrant smaller sizing, not skipping the entry entirely

→ vs conservative: FCF criticism is directionally correct but over-weighted; the 750M capacity investment and working capital absorption signals management confidence in demand, not a smoking gun for problems